GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Scientific Rationale for Atryn in DIC/Sepsis

[Added preclinical study and second paper by Wiedermann.]


Primary support

“Treatment Effects of High-Dose
Antithrombin Without Concomitant
Heparin in Patients With Severe
Sepsis With/Without Disseminated
Intravascular Coagulation”
Kienast, J et al
J Thromb Haemost. 2006 Jan;4(1):90-7
Abstract: #msg-9313165.
Paper: http://ihub.bedida.net/Key_DIC_sepsis_article.pdf


Ancillary support

[See #msg-15250714 for
supplementary references.]

“Benefit/Risk Profile of High-Dose
Antithrombin in Patients with Severe
Sepsis Treated With and Without
Concomitant Heparin”
Hoffmann, J et al
Thromb Haemost. 2006 May;95(5):850-6.
Abstract: #msg-10993909.

“Antithrombin for Severe Sepsis?
Try Again But Without the Heparin!”
Jilma, B
Thromb Haemost. 2006 May;95(5):755.
(No abstract)

“High-Dose Antithrombin in the Treatment
of Severe Sepsis in Patients with a High
Risk of Death: Efficacy and Safety”
Wiedermann, CJ
Crit Care. 2006 Feb 34(2):285-92.

“Recombinant Human Antithrombin Inhibits
Thrombin Formation and Interleukin-6
Release in Human Endotoxemia”
Leitner, JM et al
Clin Pharmacol Ther. 2006 Jan;79(1):23-34.
Abstract: #msg-9313029.

“Endogenous Anticoagulant Therapy
for Sepsis: Success and Failure”
Wiedermann, CJ
Internist (Berl). 2007 Mar 28;
Abstract: #msg-18336592


Preclinical support

“Treatment Effects of Antithrombin on Coagulation
Abnormalities in Rats With Endotoxaemia”
Qiao, YJ et al
Abstract: #msg-18166129


The original KyberSept study

“High-Dose Antithrombin in Severe
Sepsis: A Randomized Controlled Trial”
Warren, B et al
JAMA 2001 286:1869
http://scalpel.stanford.edu/articles/AT3.pdf